Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC
Portfolio Pulse from
Akeso, Inc. has completed patient enrollment for its Phase III clinical trial comparing ivonescimab and tislelizumab for first-line treatment of sq-NSCLC. The trial is significant for Akeso's development of its PD-1/VEGF bispecific antibody.
February 06, 2025 | 1:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akeso has completed patient enrollment for its Phase III trial of ivonescimab, marking a significant milestone in its drug development process. This could potentially lead to advancements in sq-NSCLC treatment.
The completion of patient enrollment in a Phase III trial is a critical step in the drug development process, indicating progress towards potential regulatory approval. This news is likely to positively impact Akeso's stock as it demonstrates advancement in their clinical pipeline.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80